Abstract:Sickle cell disease (SCD) is the monogenic hemoglobinopathy where mutated sickle hemoglobin molecules polymerize to form long fibers under deoxygenated state and deform red blood cells (RBCs) into predominantly sickle form. Sickled RBCs stick to the vascular bed and obstruct blood flow in extreme conditions, leading to acute painful vaso-occlusion crises (VOCs) - the leading cause of mortality in SCD. Being a blood disorder of deformed RBCs, SCD manifests a wide-range of organ-specific clinical complications of life (in addition to chronic pain) such as stroke, acute chest syndrome (ACS) and pulmonary hypertension in the lung, nephropathy, auto-splenectomy, and splenomegaly, hand-foot syndrome, leg ulcer, stress erythropoiesis, osteonecrosis and osteoporosis. The physiological inception for VOC was initially thought to be only a fluid flow problem in microvascular space originated from increased viscosity due to aggregates of sickled RBCs; however, over the last three decades, multiple molecular and cellular mechanisms have been identified that aid the VOC in vivo. Activation of adhesion molecules in vascular endothelium and on RBC membranes, activated neutrophils and platelets, increased viscosity of the blood, and fluid physics driving sickled and deformed RBCs to the vascular wall (known as margination of flow) - all of these come together to orchestrate VOC. Microfluidic technology in sickle research was primarily adopted to benefit from mimicking the microvascular network to observe RBC flow under low oxygen conditions as models of VOC. However, over the last decade, microfluidics has evolved as a valuable tool to extract biophysical characteristics of sickle red cells, measure deformability of sickle red cells under simulated oxygen gradient and shear, drug testing, in vitro models of intercellular interaction on endothelialized or adhesion molecule-functionalized channels to understand adhesion in sickle microenvironment, characterizing biomechanics and microrheology, biomarker identification, and last but not least, for developing point-of-care diagnostic technologies for low resource setting. Several of these platforms have already demonstrated true potential to be translated from bench to bedside. Emerging microfluidics-based technologies for studying heterotypic cell-cell interactions, organ-on-chip application and drug dosage screening can be employed to sickle research field due to their wide-ranging advantages.

Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction

Vascular pathophysiology of sickle cell disease

Sickle cell disease as a vascular disorder

Blood rheology and vascular function in sickle cell trait and sickle cell disease: From pathophysiological mechanisms to clinical usefulness

Biomechanics and biorheology of red blood cells in sickle cell anemia

Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism

Therapeutics for sickle cell disease intravascular hemolysis

Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy

Microfluidics in Sickle Cell Disease Research: State of the Art and a Perspective Beyond the Flow Problem

End Organ Affection in Sickle Cell Disease

Eicosanoid Pathways and Inflammation in Sickle Cell Vaso-Occlusion: A Review

Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review

[Hemostasis alterations in sickle cell syndrome]

Controversies in the pathophysiology of leg ulcers in sickle cell disease

Less Deformable Erythrocyte Subpopulations Biomechanically Induce Endothelial Inflammation in Sickle Cell Disease

Sickle Cell Disease: From Genetics to Curative Approaches

Enhanced Vasoconstriction in Sickle Cell Disease is Dependent on ETA Receptor Activation

Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target

Management of Acute Complications of Sickle Cell Disease

Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy

Simultaneous polymerization and adhesion under hypoxia in sickle cell disease.